^
2d
Novel genomic risk stratification model for primary high-grade malignant peripheral nerve sheath tumor (MPNST). (PubMed, J Pathol)
Collectively, genomic alterations detected by clinical NGS panels provide potential new biomarkers for risk stratification that can be integrated with conventional parameters to provide improved prognostication and guide therapeutic strategies.
Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
|
TP53 mutation • TP53 wild-type • CDKN2A deletion
|
MSK-IMPACT
3d
Combined Soft and Hard Tissue Facial Lesions In Early Childhood Pioneering the Diagnosis of the Tumor Predisposition Syndrome Neurofibromatosis Type 1. (PubMed, Cancer Diagn Progn)
In individual cases, dental findings can provide clues for estimating the timing of the interaction between PNF and hard tissues which can apparently date back to the prenatal phase. The skeletal findings can already be identified on plain radiographs of the skull.
Journal
|
NF1 (Neurofibromin 1)
4d
Immune landscape characterization of neurofibromas with atypical features in Neurofibromatosis1 reveals PD-1 and the Tim-3/Galectin-9 pathway as potential therapeutic targets. (PubMed, Acta Neuropathol Commun)
Additionally, loss of H3K27me3 was associated with even lower densities of CD3+ T-cells and CD163+ macrophages in MPNSTs, and the loss of p16 seemed to act synergistically. Taken together, these findings suggest that an immune response involving both T-lymphocytes and macrophages may play a role in controlling or delaying the malignant transformation of ANF/ANNUBPs into MPNSTs and point to IC molecules as novel immunopreventive strategies in NF1 patients with ANF/ANNUBPs.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • CASP3 (Caspase 3) • LGALS9 (Galectin 9) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
6d
Neurofibromatosis type 1 with bladder neurofibroma followed by retroperitoneal malignant peripheral nerve sheath tumor: a case report. (PubMed, Urol Case Rep)
Despite subtotal resection and pazopanib therapy, the disease progressed and the patient died at 14 years of age. This case highlights persistent functional morbidity and later malignant progression during the long-term course of NF1-associated pelvic disease.
Journal
|
NF1 (Neurofibromin 1)
|
pazopanib
8d
Trial completion date • Pan tumor
|
STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
STK11 mutation • KEAP1 mutation • NFE2L2 mutation
|
telaglenastat (CB-839)
9d
STRIvE-02: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
P1, N=68, Active, not recruiting, Seattle Children's Hospital | Trial primary completion date: Dec 2025 --> Dec 2040
Trial primary completion date
|
Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19
13d
Case Report: Partial neurectomy and limb-sparing treatment for SOX-10 expressing epithelioid malignant nerve sheath tumour of the tibial nerve. (PubMed, Front Vet Sci)
The dog improved rapidly, and at 12- and 24-month follow-ups showed no recurrence or metastasis. This case demonstrates an atypical anatomical and histopathological presentation of canine EMPNST and shows that complete limb-sparing partial neurectomy can achieve long-term remission without compromising limb function.
Journal
|
SOX10 (SRY-Box 10)
13d
A case report of malignant transformation in neurofibromatosis type 1: pain and rapid growth as key indicators for early biopsy. (PubMed, Front Oncol)
No adjuvant targeted therapy was administered, and no recurrence was observed during the six-month follow-up. This case highlights the coexistence of NF1 and MPNST, aiming to enhance clinical awareness of the malignant transformation risks in NF1, thereby promoting earlier diagnosis and minimizing the potential for misdiagnosis and delayed intervention.
Journal
|
NF1 (Neurofibromin 1)
14d
New P1/2 trial
|
MTAP (Methylthioadenosine Phosphorylase)
|
MTAP deletion
|
navlimetostat (BMS-986504)
15d
Pelvic Malignant Peripheral Nerve Sheath Tumor Revealing Previously Undiagnosed Familial Neurofibromatosis Type 1 in a Nine-Year-Old Girl: A Case Report. (PubMed, Cureus)
The patient was started on doxorubicin and ifosfamide chemotherapy. This case emphasizes that systematic cutaneous assessment in children with deep, rapidly growing soft tissue masses can be pivotal for identifying NF1, refining the differential diagnosis toward MPNST, and accelerating appropriate staging and multidisciplinary management.
Journal
|
NF1 (Neurofibromin 1) • SOX10 (SRY-Box 10) • CD99 (CD99 Molecule)
|
doxorubicin hydrochloride • ifosfamide
15d
A case of retroperitoneal malignant schwannoma in a young male: a case report. (PubMed, J Med Case Rep)
This case underscores that a large, well-circumscribed retroperitoneal peripheral nerve sheath tumor in a young adult may still be malignant. Pathology-driven risk stratification with quantified mitotic activity and Ki-67 is essential for accurate classification and for planning structured post-resection surveillance.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
15d
Sox2 protein stability is enhanced by BRafV600E and Pten deletion in adult neural stem/progenitor cells. (PubMed, NPJ Precis Oncol)
BRaf-mutant aNSPCs display increased Sox2 protein, but not mRNA levels, suggesting post-transcriptional regulation. Sox2 phosphorylation at T118 is promoted by BRafV600E, potentially stabilizing the protein during aNSPC transformation, although the involvement of downstream kinases cannot be excluded.
Journal
|
BRAF (B-raf proto-oncogene) • PTEN (Phosphatase and tensin homolog) • SOX2
|
BRAF V600E • BRAF V600 • PTEN deletion • PTEN mutation